Media Room

Latest News Releases

Aug 8, 2019

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2019. Cash and investments in marketable securities at June 30, 2019 were $1.8 billion...

Aug 1, 2019

Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for...

Jul 30, 2019

Nektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 8, 2019, after the close of U.S.-based financial markets. Howard Robin, President...

Multimedia Libraries

Broadcast Video

Image Gallery

Media Contacts

Dan Budwick
Pure Communications, Inc.
Media@purecommunications...

Follow @NektarNews

Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide